Treatment for inattentive ADHD typically includes behavioral therapy and medication. Stimulant medications like methylphenidate and amphetamine salts are commonly prescribed. Non-stimulant options such as atomoxetine are also used when stimulants cause side effects. Companies like Shire plc, now part of Takeda Pharmaceutical, have developed several ADHD medications over the years. The global ADHD therapeutics market was valued at over $15 billion in recent years, with projections for continued growth. Digital health companies such as Akili Interactive are developing prescription video games like EndeavorRx, which received FDA authorization as a treatment for pediatric ADHD. The effectiveness of these interventions varies by individual, and a thorough evaluation by a qualified clinician remains essential.
Hyperactive-Impulsive ADHD
Hyperactive-impulsive ADHD is the least common of the three types and is marked by excessive fidgeting, inability to stay seated, and impulsive decision-making. Individuals with this presentation often interrupt others, blurt out answers, and struggle with patience. This form is more frequently identified in children, especially boys, though it can persist into adulthood. The DSM-5 criteria require that several hyperactive-impulsive symptoms be present for at least six months. Public awareness of this type has grown, partly due to high-profile individuals speaking openly about their experiences. For a detailed breakdown of symptoms, refer to the National Institute of Mental Health ADHD page.
Managing hyperactive-impulsive ADHD often involves a combination of medication and behavioral strategies. Companies like Johnson & Johnson and Novartis produce widely prescribed stimulant formulations. Behavioral interventions focus on teaching impulse control and organizational skills. Schools and workplaces increasingly implement structured environments to support individuals with this type. Insurance coverage for ADHD treatment varies, and out-of-pocket costs can be significant without proper planning. The SEC filings of major pharmaceutical companies regularly disclose details about ADHD drug sales and pipeline developments, offering transparency into market trends. For financial analysis of ADHD-related investments, see the SEC EDGAR database.
Combined ADHD
Combined ADHD is the most prevalent presentation, involving a mix of inattentive and hyperactive-impulsive symptoms. It accounts for the majority of ADHD diagnoses in both children and adults. To be classified as combined type, an individual must meet the symptom thresholds for both inattentive and hyperactive-impulsive presentations. This combination often presents the greatest challenge in academic and professional settings. Research indicates that combined ADHD has a strong genetic component, with heritability estimates around 74%. The condition is also associated with higher rates of comorbid disorders such as anxiety and learning disabilities. For current research findings, visit the CDC ADHD data and research page.
Treatment for combined ADHD is typically multimodal, integrating medication, therapy, and lifestyle adjustments. Major pharmaceutical companies like Teva Pharmaceutical and Lundbeck invest heavily in ADHD drug development. Behavioral therapy, particularly cognitive behavioral therapy, has shown strong efficacy for adults